Document:

Exhibit
10.15

 

Certain portions of this
Exhibit have been omitted pursuant to a request for confidentiality. Such
omitted portions, which are marked with brackets [   ] and an asterisk*, have been separately
filed with the Commission.

 

LICENSE
AGREEMENT

 

THIS
LICENSE AGREEMENT (the “Agreement”) is made and entered into as of this 3rd day of February, 2003
(the “Effective Date”) by and between ACORDA THERAPEUTICS, INC., a corporation organized and
existing under the laws of the state of Delaware having a principal place of
business at 15 Skyline Drive, Hawthorne, New York 10532 (“Acorda”)
and CORNELL RESEARCH FOUNDATION, INC., a
non-profit corporation organized and existing under the laws of the state of
New York having an office at 20 Thornwood Drive, Suite 105, Ithaca, NY  14850 (“Foundation”).
Each of Acorda and Foundation may be referred to herein individually as a “Party” and collectively, as “Parties.”

 

RECITALS

 

WHEREAS,
Foundation owns all right, title and interest in U.S. Patent No. 5,952,357; and

 

WHEREAS, Foundation
is a wholly owned subsidiary of Cornell University (“Cornell”) and holds the
ownership interests of patents, know-how, and biological materials made by
Cornell’s employees and administers licenses in a manner consistent with the
policies of Cornell; and

 

WHEREAS, Acorda
desires to obtain and Foundation wishes to grant to Acorda, an exclusive
license to U.S. Patent No. 5,952,357, including all intellectual property
rights therein, for the development and commercialization of pharmaceutical products
for all purposes; and

 

WHEREAS, the
work leading to the Licensed Patents was supported in part by an agency of the
U.S. Government, and Foundation is obligated to comply with U.S. OMB Circular
A-124 and 37 CFR Part 401; and as such, this license is subject to the
applicable terms of U.S. Government regulations concerning Government funded
inventions.

 

NOW,
THEREFORE, for and in consideration of the mutual covenants
and the premises herein contained, the Parties, intending to be legally bound,
hereby agree as follows:

 

ARTICLE 1

 

DEFINITIONS

 

The following terms as
used herein shall have the following meanings:

 

1.1          “Affiliate” shall
mean any corporation or non-corporate business entity which controls, is
controlled by, or is under common control with a Party to this Agreement.  A corporation or non-corporate business
entity shall be regarded as in control of another corporation if it owns, or
directly or indirectly controls, at least fifty (50%) percent of the voting
stock of the other corporation, or (a) in the absence of the ownership of at
least fifty (50%) percent of the voting stock of a corporation or (b) in the
case of a non-corporate business entity, or non-profit corporation, if it
possesses, directly or indirectly, the power to direct or cause the

 

 

direction of the
management and policies of such corporation or non-corporate business entity,
as applicable.

 

1.2          “Clinical Trial”
shall mean one of those trials on sufficient number of subjects that are
designed to establish that a pharmaceutical product is safe and efficacious for
its intended use, to define warnings, precautions and adverse reactions that
are associated with the pharmaceutical product or label expansion of such
pharmaceutical product.

 

1.3          “Dollars” shall mean
United States dollars.

 

1.4          “Earned Royalties” shall
mean royalties payable to Foundation by Acorda for the Sale of a
Royalty-Bearing Product, as provided in Section 3.2.

 

1.5          “FDA” shall mean the
United States Food and Drug Administration or successor entity.

 

1.6          “Licensed Patents” shall
mean U.S. Patent No. 5,952,357, together with any and all substitutions,
extensions, divisionals, continuations, or continuations-in-part of such patent
(or its parent application), including reexamined and reissued patents, and all
foreign counterparts of any of the foregoing.

 

1.7          “Licensed Product” shall
mean any product or process that is covered by, or the manufacture or use of
which is covered by, a Valid Claim.

 

1.8          “Licensed Territory” shall
mean the world.

 

1.9          “Net Sales” shall
mean the actual amounts received by Acorda or an Affiliate or sublicensee of
Acorda for the Sale of Royalty-Bearing Products to a Third Party purchaser less
the following deductions to the extent that such amounts are actually accrued
or incurred as to such sales: (a) freight, packaging and insurance costs
incurred in transporting the Royalty-Bearing Product to such customers; (b)
quantity, cash and other trade discounts or rebates actually allowed and taken,
including without limitation, discounts or rebates granted to managed health
care organizations or to any governmental agency or branch thereof; (c) customs
duties, surcharges, taxes and other governmental charges incurred in connection
with the exportation or importation of such Royalty-Bearing Products; and (d)
amounts repaid or credited by reason of rejections, recalls or retroactive
price reductions.

 

1.10        “Regulatory Approval” shall
mean the approvals, registrations or authorizations of the FDA or other
applicable regulatory agency necessary for the manufacture, distribution, use
or sale of a pharmaceutical or diagnostic product in the United States.

 

1.11        “Royalty-Bearing Product” shall
mean the product known as Fampridine-SR for all indications.

 

1.12        “Sale” or “Sold” shall mean the sale, transfer, exchange, or other
commercial disposition of Royalty-Bearing Products by Acorda, its Affiliates or
sublicensees.  In case of doubt, Sales of
Royalty-Bearing Products shall be deemed consummated no later than receipt of

 

2

 

payment from a Third
Party for the applicable transaction involving such Royalty Bearing Product.

 

1.13        “Third Party” shall
mean any entity or individual other than Acorda, Foundation or an Affiliate of
either of them.

 

1.14        “Valid Claim” shall
mean: (a) an issued claim of any unexpired patent included among the Licensed
Patents, which patent has not been (i) held unenforceable, unpatentable or
invalid by a decision of a court or governmental body of competent jurisdiction
that is not further appealable, (ii) rendered unenforceable through
reexamination, reissue, disclaimer or otherwise, (iii) lost through an
interference proceeding or (iv) abandoned; or (b) a claim of a pending
application within the Licensed Patents, provided that not more than five (5)
years have elapsed from the date the claim takes priority for filing purposes.

 

ARTICLE 2

 

GRANT
OF LICENSE

 

2.1          License.  Subject to the terms and conditions of this
Agreement and to the rights of and obligations to the U.S. Government as set
forth in U.S. Office of Management & Budget Circular A-124 or 37 CFR Part
401 et seq., Foundation hereby grants to Acorda and its Affiliates and Acorda
hereby accepts an exclusive, fully sublicenseable license under the Licensed
Patents to practice the inventions claimed therein and to research, develop,
make, have made, use, sell, offer for sale, have sold, import and otherwise
exploit Licensed Products in the Licensed Territory during the term of this
Agreement.

 

2.2          Retained License.  The license granted in Section 2.1 above are
further subject to a right and license retained by Foundation and Cornell to
practice the Licensed Patents and any improvements thereto for non-commercial
academic research and education purposes only.

 

2.3          Sublicenses.  Acorda may grant sublicenses to Third Parties
under the license in Section 2.1 to practice Licensed Patents and to research,
develop, make, have made, use, sell, offer for sale, have sold, import or
otherwise exploit Licensed Products upon prior written approval by Foundation,
such approval not to be unreasonably withheld or delayed.  If Acorda fails to obtain the prior written
consent of Foundation to a sublicense agreement, Foundation shall have the
right to either terminate this Agreement pursuant to Section 10.3 or require
that the sublicense be terminated.  Any
such sublicense shall contain all the provisions of this Agreement which are
protective of and beneficial to Foundation and Acorda shall be responsible to Foundation
for the payment of Earned Royalties on Net Sales made by such sublicensees as
though they were Net Sales made by Acorda.

 

2.4          No Implied License.  The license and rights granted in this
Agreement shall not be construed to confer any rights upon Acorda by
implication, estoppel, or otherwise as to any technology not specifically
identified in this Agreement as Licensed Patents.

 

2.5          Government Regulations.  Acorda shall alone have the
obligation to ensure that any Licensed Product it makes, uses, or sells,
leases, or otherwise disposes of is not defective,

 

3

 

Certain portions of this Exhibit have been omitted pursuant to a
request for confidentiality. Such omitted portions, which are marked with
brackets [   ] and an asterisk*, have
been separately filed with the Commission.

 

that any Licensed Product
satisfies all applicable government regulations and that any export of any
Licensed Product satisfies export requirements.

 

ARTICLE 3

 

COMPENSATION

 

3.1          License Execution Fee.  Within ten (10) days of the Effective Date,
Acorda shall pay Foundation a license execution fee of [**].

 

3.2          Earned Royalties on Royalty-Bearing
Products.  For Sales of
Royalty-Bearing Product in the Licensed Territory, Acorda shall pay or cause to
be paid to Foundation Earned Royalties equal to the following percentages of
the aggregate annual Net Sales of such Royalty-Bearing Product by Acorda, its
Affiliates and its sublicensees:

 

(a)           for the portion of
such aggregate annual Net Sales of such Royalty-Bearing Product less than [**]
in any calendar year, [**] of such Net Sales;

 

(b)           for the portion of
such aggregate annual Net Sales of such Royalty-Bearing Product between [**]
and up to [**] in any calendar year, [**] of such Net Sales; and

 

(c)           for the portion of
such aggregate annual Net Sales of such Royalty-Bearing Product greater than
[**] in any calendar year, [**] of such Net Sales.

 

3.3          Annual Minimum Royalty.

 

(a)           Subject to Section
3.3(b), if Acorda’s annual Earned Royalties payment for the Royalty-Bearing Product
to Foundation pursuant to Section 3.2 after the first full calendar year
anniversary following the date of Regulatory Approval for the Royalty-Bearing
Product, or in any calendar year thereafter, is less than [**] (the “Minimum Royalty”), Acorda shall make or cause to be made a
payment to Foundation within sixty (60) days after the end of such applicable
calendar year equal to the difference between the Minimum Royalty and the total
Earned Royalties payment to Foundation for all Royalty-Bearing Products for
that calendar year, together with the applicable report in accordance with
Article 4.

 

(b)           If during a given
calendar year, the Earned Royalties payment to Foundation pursuant to Section
3.2 for Royalty-Bearing Products exceeds the Minimum Royalty for such year
pursuant to Section 3.3(a), Acorda shall have satisfied the requirements of
Section 3.3(a) for such year without any additional payment needed.

 

3.4          Milestone Payments.  Acorda shall pay Foundation
a milestone payment in the amount specified below no later than [***] days
after the occurrence of Milestone 1 and [***] days after the occurrence of
Milestone 2, both milestones as defined below.

 

4

 

Certain portions of this
Exhibit have been omitted pursuant to a request for confidentiality. Such
omitted portions, which are marked with brackets [   ] and an asterisk*, have been separately
filed with the Commission.

 

	
  Event

  	
   

  	
  Milestone Payment

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  (i) The effective date of a successful reissuance or
  reexamination of the Licensed Patents (“Milestone 1”).

  	
   

  	
  $

  	
  [**]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  (ii) The date of completion of a Clinical Trial
  testing the use of Fampridine-SR in Amyotrophic Lateral Sclerosis (ALS),
  provided that such Clinical Trial shall be initiated at Acorda’s discretion
  and a negative or non-statistically significant trial would not trigger this
  milestone (“Milestone 2”).

  	
   

  	
  $

  	
  [**]

  	
   

  

 

No milestone
payment shall be paid more than once to Foundation pursuant to this Section
3.4.  Milestone 1 and Milestone 2 are
independent of each other and Milestone 2 may occur prior to Milestone 1.  In any event, Acorda shall pay the specified
milestone payment only upon the occurrence of the corresponding milestone
event, regardless of the order of occurrence of the milestone events.

 

3.5          Research Support.   Pursuant to a sponsored research agreement to
be negotiated by the Parties, Acorda shall pay Foundation [**] per year for
research support for two (2) years beginning the first full calendar year of
commercial sales for the Royalty-Bearing Product, Fampridine-SR.  Such sponsored research agreement shall
include commercially reasonable terms and conditions as are typical for
sponsored research agreements of similar nature in the biotechnology industry
as discussed and agreed upon in good faith by the Parties, and further, shall
provide that the payment for the first year shall be due within sixty (60) days
after the commencement of commercial sales for the Royalty-Bearing Product
while the second payment shall be due within sixty (60) days after the first
anniversary of commercial sales for the Royalty-Bearing Product.

 

ARTICLE 4

 

REPORTS,
PAYMENTS AND ACCOUNTING

 

4.1          Earned Royalties Reports and Records.  During the term of this Agreement, Acorda
shall furnish, or cause to be furnished to Foundation, quarterly written
reports governing each of Acorda and its Affiliates and sublicensees for each
fiscal quarter showing, as applicable:

 

(a)           the gross sales of
all Royalty Bearing Products Sold by Acorda, its Affiliates and sublicensees,
in the Licensed Territory during the reporting period, together with the
calculations of Net Sales in accordance with Section 1.9;

 

(b)           the Earned
Royalties payable in Dollars, which shall have accrued hereunder in respect to
such Net Sales;

 

(c)           the exchange rates,
if any, in determining the amount of Dollars; and

 

5

 

(d)           the occurrence of
any event triggering a milestone payment obligation in accordance with Section
3.4.

 

4.2          Payment Terms.  Acorda shall provide Foundation with quarterly
written reports of all sales, or other dispositions of Licensed Products by
Acorda and its Affiliates and sublicensees. 
In order to minimize Acorda’s time spent on royalty reports, a brief
one-page report form (a “Royalty Report Form”),
substantially the same as the form attached in Appendix A, will satisfy
Foundation’s reporting requirements under this Section 4.2.  The report shall be made within forty-five
(45) days after the end of each calendar quarter; provided,
however, that if an Acorda sublicense provides that the sublicensee
can submit its respective reports to Acorda forty-five (45) days or more after
the end of each calendar quarter, Acorda may then delay submitting its royalty
report under this Section 4.2 to Foundation with respect to such sublicensee
until sixty (60) days after the end of each calendar quarter.  Foundation agrees to keep the information in
these reports confidential, except as may be necessary to maintain an action
against Acorda for breach of this Agreement. 
Royalty payments for Net Sales of the Licensed Products invoiced during
a calendar quarter shall accompany the Royalty Report Form for that
quarter.  The Royalty Report Form shall
be submitted regardless of whether or not royalties are owed.  Payments shall be made in Dollars.  Conversion from foreign currencies, if any,
shall be based upon the conversion rate published in The Wall
Street Journal on the last day of the particular quarterly
accounting period (or on the last business day on which The Wall
Street Journal is published during said quarterly period) for which
royalties are due.  Royalty checks shall
be made payable to Cornell Research Foundation Inc. and mailed to the address
specified in Section 12.11.

 

4.3          Minimum Royalty Calculation.  Acorda shall provide in the Royalty Report
Form for the last quarter in each calendar year, the total Earned Royalties
paid by Acorda to the Foundation for such calendar year and if such total is
less than the Minimum Royalty, Acorda shall pay Foundation an amount equal to
the difference between the total Earned Royalties paid in such calendar year
and the Minimum Royalty.

 

4.4          Right to Audit.  Foundation shall have the right, upon prior
written notice to Acorda, not more than once in each Acorda fiscal year, to
engage an independent nationally-certified auditing firm selected by Foundation
and acceptable to Acorda, which acceptance shall not be unreasonably withheld
or delayed, to have access during normal business hours of Acorda as may be
reasonably necessary to verify the accuracy of the Earned Royalties reports
required to be furnished by Acorda pursuant to Section 4.1 of the
Agreement.  If such audit by Foundation
shows any underpayment of Earned Royalties by Acorda, its Affiliates or sublicensees,
then, within thirty (30) days after Acorda’s receipt of such report, Acorda
shall remit or shall cause its sublicensees to remit to Foundation:

 

(a)           the amount of such
underpayment; and

 

(b)           if such
underpayment exceeds five percent (5%) of the total Earned Royalties owed for
the fiscal year then being reviewed, the reasonably necessary fees and expenses
of such auditing firm performing the audit. 
Otherwise, such fees and expenses shall be borne solely by
Foundation.  Any overpayment of Earned
Royalties shall be fully creditable against future Earned Royalties payable in
any subsequent royalty period.

 

6

 

4.5          Confidentiality of Records.  All information subject to review under this
Article 4 shall be deemed Acorda’s Confidential Information (as defined in
Section 9.1). The independent nationally-certified auditing firm shall not
disclose to Foundation or to any Third Party any such Confidential Information,
except for any Confidential Information showing a discrepancy in amount owed to
Foundation, and Foundation shall not use any such information for any purpose
other than determining and enforcing its rights under this Agreement.  Foundation agrees to hold such records
confidential, except as may be necessary to maintain an action against Acorda
for breach of this Agreement.

 

4.6          The records required under Article 4
shall be maintained and available for inspection for a period of five (5) years
following the calendar quarter to which they pertain.  This Section 4.6 shall survive termination of
this Agreement.

 

4.7          Payments due under this Agreement that
are more than the sixty (60) days late shall be subject to a twenty percent
(20%) per annum interest charge.

 

4.8          Acorda shall keep Foundation appropriately
informed about Acorda’s development and commercialization efforts with respect
to Licensed Products.  Without limiting
the generality of the foregoing, Acorda shall provide Foundation with written
notice of significant development, regulatory approval and commercialization
plans, activities and results with respect to Licensed Products.  In addition, on each anniversary of the
Effective Date during the term of this Agreement (commencing with the first (1st)
anniversary thereof), Acorda shall provide Foundation with a written annual
report summarizing Acorda’s efforts and progress in developing and
commercializing Licensed Products during the immediately preceding twelve (12)
months.

 

ARTICLE 5

 

PATENTS
AND PATENT COSTS

 

5.1          Prosecution and Maintenance of
Licensed Patents.  Foundation
shall be primarily responsible for all patent prosecution and maintenance
activities pertaining to Licensed Patents. 
Foundation shall keep Acorda reasonably informed of its activities
relating to the filing, prosecution and maintenance of Licensed Patents,
including providing copies of all filings and correspondence with patent
authorities, in a timely manner, so as to give Acorda an opportunity to comment
thereon.  Foundation shall use good faith
efforts to accommodate all such comments. 
Without limiting the generality of the foregoing, Foundation shall work
collaboratively with Acorda to secure the reissuance or reexamination of the
Licensed Patents in a manner acceptable to Foundation and Acorda.  Acorda agrees to keep any documentation
received under this Section 5.1 confidential in accordance with Article 9
herein.

 

5.2          Future Patent Costs.  Acorda shall pay all fees
and out-of-pocket costs incurred by
Foundation pursuant to its activities under Section 5.1 after the Effective
Date for on-going patent prosecution and maintenance activities for the
Licensed Patents (the “Future Patent Costs”).  Acorda shall reimburse Foundation, no later
than thirty (30) days after receipt of an invoice from Foundation for such
Future Patent Costs.

 

7

 

5.3          Acorda’s Payment Obligation.  Acorda’s obligation, pursuant to Section 5.2
to pay for domestic and foreign patent filing, prosecution, and maintenance
costs for Licensed Patents shall continue for so long as this Agreement remains
in effect, provided, however, that Acorda may terminate its obligations with
respect to any given patent application or patent in the Licensed Patents in
any particular country or jurisdiction upon thirty (30) days written notice to
Foundation, provided, further, that Acorda’s rights under such patent
applications or patents in such countries, for which it has terminated its
payment obligations pursuant to this Section 5.3, shall terminate.  Patent costs already committed to prior to
the date of the termination notice and which are not cancelable, shall be the
responsibility of Acorda and shall survive termination of this Agreement.

 

ARTICLE
6

 

INFRINGEMENT

 

6.1          Enforcement of Patents.  If either Acorda or Foundation becomes aware
of a product made, used or sold in the Licensed Territory, which it believes
infringes a Valid Claim, the Party obtaining such knowledge shall promptly
advise the other Party of all relevant facts and circumstances pertaining to the
potential infringement.  Acorda shall
have the first right, but not the obligation, to enforce any patent rights
within the Licensed Patents against such infringement, at its own expense.  Foundation shall cooperate with Acorda in
such effort, at Acorda’s expense, including being joined as a Party to such
action, if necessary.  Any damages or
costs recovered in connection with any action filed by Acorda hereunder which
exceed Acorda’s out-of-pocket costs and expenses of litigation, shall be deemed
to be the proceeds of Sales of Royalty-Bearing Products in the fiscal quarter
received by Acorda, and Earned Royalties shall be payable by Acorda to
Foundation thereon in accordance with the terms of this Agreement.

 

6.2          Backup Enforcement Right of
Foundation.  If Acorda
fails within one hundred twenty (120) days after receiving notice from
Foundation of a potential infringement, or providing Foundation with notice of
such infringement, to either (a) terminate such infringement or (b) institute
an action to prevent continuation thereof and, thereafter to prosecute such
action diligently, or if Acorda notifies Foundation that it does not plan to
terminate the infringement or institute such action, then Foundation shall have
the right to do so at its own expense; provided however, that Foundation first
consults with Acorda and gives due consideration to Acorda’s reasons for not
instituting actions to terminate or otherwise prevent continuation of such
infringement.  If Foundation decides to
pursue such infringement, Acorda shall cooperate with Foundation in such effort
including being joined as a Party to such action if necessary.  Foundation shall be entitled to retain all
damages or costs awarded to Foundation in such action.

 

8

 

ARTICLE 7

 

REPRESENTATIONS
AND WARRANTIES; EXCLUSION OF WARRANTIES

 

7.1          Foundation
Representations and Warranties.

 

(a)           Foundation
represents and warrants that it has the right to enter into this
Agreement.  Foundation warrants that it
has the right to convey to Acorda the rights granted under this Agreement.

 

(b)           Foundation warrants
that it is the sole owner of Licensed Patents prior to the effective date of
this Agreement, and has not granted any license or other rights to any third
party under the Licensed Patents which rights are still in existence, subject
to U.S. government regulations concerning government funded inventions.

 

(c)           Foundation makes no representation or
warranty that Licensed Patents will be reissued.

 

(d)           Foundation makes no representations
or warranties concerning the validity or scope of any Licensed Patents.

 

(e)           Foundation does not warrant that any
Licensed Product made, used, sold, leased or otherwise disposed of under the
license of this Agreement is or will be free from infringement of patents of
third parties.

 

(f)            Nothing herein shall be construed as
granting by implication, estoppel, or otherwise any licenses or rights under
patents or other rights of Foundation or Cornell or other persons other than
Licensed Patents, regardless of whether such patents or other rights are
dominant or subordinate to any Licensed Patents.

 

(g)           Foundation is under no obligation to
furnish any technology or technological information other than the Licensed
Patents.

 

(h)           Nothing herein shall be construed to
grant Acorda rights under any applications or patents other than Licensed
Patents.

 

(i)            Foundation does not make any
representations, extend any warranties of any kind, express or implied, or
assume any responsibility whatever concerning the manufacture, use, or sale,
lease or other disposition by Acorda or its vendees or transferees of Licensed
Products.

 

(j)            Except as expressly set forth in
this Agreement, FOUNDATION MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES
OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE
USE OF THE LICENSED PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK, OR OTHER RIGHTS OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES.

 

7.2          Acorda Representations and Warranties.  Acorda represents, warrants and covenants to
Foundation that:

 

(a)           this Agreement is a
legal and valid obligation of, binding upon, and enforceable against Acorda in
accordance with the terms of this Agreement;

 

9

 

(b)           Acorda has the
right to enter into this Agreement and perform the obligations set forth in
this Agreement; and

 

(c)           the execution,
delivery and performance of this Agreement does not conflict with, constitute a
breach of, or in any way violate any arrangement, understanding or agreement to
which Acorda is a party or by which Acorda is bound.

 

ARTICLE 8

 

INDEMNIFICATION;
LIMITATION OF LIABILITY 

 

8.1          Indemnification by Acorda.  Acorda shall defend,
indemnify and hold harmless Foundation and Cornell and their respective
trustees, officers, directors, employees, agents and students (the “Foundation Indemnitees”), from and against any and all
losses, liabilities, expenses or damages (including reasonable attorneys’ fees)
(collectively, the “Losses”)
resulting from claims made or legal proceedings instituted, made or brought
against Foundation and/or Cornell by a Third Party arising or alleged to arise
by reason of, or in connection with, any and all personal injury (including
death) and property damage caused or contributed to, in whole or in part, by
the manufacture, testing, design, use, Sale or labeling of any Licensed
Products by Acorda, its Affiliates, contractors, agents, or sublicensees,
except to the extent of any Losses that arise from the negligence or
intentional misconduct of Foundation Indemnitees.

 

8.2          In the event
Foundation is found to be in breach of Sections 7.1(a) and/or 7.1(b) of this
Agreement, Foundation shall use its best efforts to remedy such breach within
ninety (90) days of receipt by Foundation of written notification that such a
breach has occurred.  If Foundation is
unable to remedy such breach within ninety (90) days after receiving such
written notification of a breach, Foundation shall use its best efforts to
obtain the right to grant, and to grant to Acorda, a non-exclusive, fully
sublicenseable license under the Licensed Patents to practice the inventions
claimed therein and to research, develop, make, have made, use, sell, offer for
sale, have sold, import and otherwise exploit Licensed Products in the Licensed
Territory pursuant to a new license agreement, the terms of which will be
negotiated in good faith by the Parties (which terms shall be no less favorable
to Acorda than the terms of this Agreement). 
Foundation shall not be liable for any indirect, special, consequential,
or other damages whatsoever, whether grounded in tort (including negligence),
strict liability, contract or otherwise. Foundation shall not have any
responsibilities or liabilities whatsoever with respect to Licensed Products.

 

8.3          Indemnification Procedure.  To be indemnified hereunder, the Foundation
shall provide Acorda with prompt notice of the claim giving rise to the
indemnification obligation pursuant to this Article 8 and the exclusive ability
to defend (with the reasonable cooperation of Foundation) or settle any such
claim provided however, that Acorda shall not
enter into any settlement for damages other than monetary damages without the
Foundation’s written consent, such consent not to be unreasonably withheld or
delayed.  The Foundation shall have the
right to participate, at its own expense and with counsel of its choice, in the
defense of any claim or suit that has been assumed by Acorda.

 

10

 

8.4          Insurance.  Acorda shall maintain commercially reasonable
levels of insurance or other adequate forms of protection to satisfy its
indemnification obligations under this Agreement.

 

ARTICLE 9

 

CONFIDENTIALITY

 

9.1          Nondisclosure of Confidential
Information.  Except as
otherwise provided hereunder, during the term of this Agreement and for a
period of five (5) years thereafter, Acorda and Foundation each agrees to
retain in strict confidence, use only for the purposes of this Agreement, and
not disclose any written information or data supplied by one Party to the other
under this Agreement and marked as proprietary or confidential without the
prior written consent of the disclosing Party. 
For purposes of this Agreement, all such information and data which a
Party is obligated to retain in confidence shall be “Confidential
Information.”

 

9.2          Permitted Disclosure.  It shall not be a breach of this Article 9 if
the recipient Party is required to disclose the other Party’s Confidential
Information pursuant to an order of the government or a court of competent
jurisdiction, provided that the recipient Party (a) provides the other Party
with adequate notice of the required disclosure, (b) cooperates with the other
Party’s efforts to protect its Confidential Information with respect to such
disclosure and (c) takes all reasonable measures requested by the other Party
to challenge or to modify the scope of such required disclosure.  To the extent that it is reasonably necessary
to fulfill its obligations or exercise its rights under this Agreement, or any
rights which survive termination or expiration hereof, the recipient Party may
disclose Confidential Information of the other Party to its Affiliates,
sublicensees, consultants, outside contractors and clinical investigators
provided that such entities or persons are bound by obligations of
confidentiality and non-use as strict as the obligations in this Agreement and
agree to use the Confidential Information only for such purposes as the
recipient Party is authorized to use the Confidential Information.

 

9.3          Exceptions.  The obligation under Section 9.1 not to use
or disclose Confidential Information shall not apply to any part of such Confidential
Information that the recipient Party can establish by competent written proof:

 

(a)           is or becomes
patented, published or otherwise part of the public domain, other than by
unauthorized acts of the recipient Party obligated not to disclose such Confidential
Information, its Affiliates or sublicensees in contravention of this Agreement;

 

(b)           is disclosed to the
recipient Party, its Affiliates or sublicensees by a Third Party having the
right to disclose it;

 

(c)           prior to disclosure
under this Agreement, was already in the possession of the recipient Party, its
Affiliates or sublicensees, as proven through contemporaneous documentation;

 

(d)           results from the
research and development by the recipient Party, its Affiliates or
sublicensees, independent of disclosures from the disclosing Party of this

 

11

 

Agreement, provided that
the persons developing such information have not had exposure to the
Confidential Information received from the disclosing Party; or

 

(e)           Acorda and
Foundation agree in writing may be disclosed.

 

9.4          Publication.  It is the policy of Foundation and Cornell to
promote and safeguard free and open inquiry by faculty, students and
others.  To further this policy,
Foundation and Cornell shall retain the right to publish the technology
described in Licensed Patents. 
Foundation and Cornell shall use reasonable efforts to furnish Acorda
with a copy of any proposed publication relating to the Licensed Products at
least sixty (60) days in advance of the publication date.  Within this sixty (60) day period, Acorda
shall review such proposed publication to determine whether Acorda desires to
file patent applications on subject matter contained therein and if it is
determined that a patent application should be filed, such patent application
shall be filed within this sixty (60) day period.

 

ARTICLE 10

 

TERM
AND TERMINATION

 

10.1        Term.  Unless sooner terminated as otherwise
provided in this Agreement, the term of this Agreement shall commence on the
Effective Date hereof and shall continue in full force and effect until the
expiration of the last to expire Valid Claim.

 

10.2        Termination by Acorda.  Acorda may terminate this Agreement at any
time upon forty five (45) days prior written notice to Foundation.

 

10.3        Termination for Material Breach.  If either Party breaches a material
obligation under this Agreement, the other Party shall have the right to give
the breaching Party written notice describing the alleged breach.  If the breaching Party does not cure such
breach within sixty (60) days after receipt of such notice, the notifying Party
may, in addition to any other rights it may have under this Agreement,
terminate this Agreement effective immediately. 
However, if there is a dispute between the Parties as to termination
under this Section 10.3, no termination shall be effected until such dispute is
resolved pursuant to Section 12.1.

 

10.4        Upon termination of
this Agreement for any reason, including the end of term as specified above,
all rights and obligations under this Agreement shall terminate, except those
that have accrued prior to termination and except as specified in the
Agreement.

 

ARTICLE 11

 

ASSIGNMENT

 

Neither Party may
assign or transfer this Agreement or any rights or obligations hereunder
without the prior written consent of the other, except a Party may make such an
assignment without the other Party’s written consent to an Affiliate or to a
successor to all, or substantially all, of the business to which this Agreement
relates of such Party, whether in a merger, sale of stock, sale of assets or
other transaction. Any permitted successor or assignee of rights and/or
obligations hereunder shall, in writing to the other Party, expressly assume

 

12

 

performance of such
rights and/or obligations.  Any permitted
assignment shall be binding on the successors of the assigning Party.  Any assignment or attempted assignment by either
Party in violation of the terms of this Article 11 shall be null and void and
of no legal effect.

 

ARTICLE 12

 

MISCELLANEOUS

 

12.1        Dispute Resolution.  If any disputes, controversies or claims
arise out of, or in connection with, this Agreement (each, a “Dispute”), the Parties shall notify each other in writing of
such Dispute and will use good faith efforts to resolve the Dispute.  If the Parties are unable to resolve such
Dispute within ten (10) business days of a Party receiving notification from
the other Party and requesting resolution of such Dispute, then either Party
may, for a period of thirty (30) days thereafter, request in writing that such
Dispute be resolved through arbitration, and such arbitration shall be
conducted under the auspices of the American Arbitration Association pursuant
to that organization’s rules for commercial arbitration.  If neither Party requests to resolve the
Dispute through arbitration within such thirty (30) day period, then either
Party may pursue resolution through any court of competent jurisdiction in
accordance with Section 12.7. 
Notwithstanding the foregoing, either Party may apply to a court of
competent jurisdiction for a temporary restraining order, a preliminary or
permanent injunction, or other equitable relief.

 

12.2        Notwithstanding
Section 12.1, Foundation reserves the right and power to proceed with direct
judicial remedies against Acorda without conciliation, mediation, mediation,
arbitration or disputer resolution for breach of the royalty and/or milestone
payments and sales reporting provisions of this Agreement after giving written
notice of such breach to Acorda followed by an opportunity period of sixty (60)
days in which to cure such breach.  In
collecting overdue royalty and milestone payments and securing compliance with
reporting obligations, Foundation may use all judicial remedies available.

 

12.3        Legal Compliance.  Acorda shall comply with all laws and
regulations relating to its manufacture, use, Sale, labeling or distribution of
Licensed Products and shall not take any action which would cause Foundation or
Acorda to violate any applicable laws or regulations.

 

12.4        Independent Contractor.  Acorda’s relationship to Foundation shall be
that of a licensee only.  Neither Party
shall be considered to be an employee or agent of the other, nor shall this
Agreement constitute, create or in any way be interpreted as a joint venture,
partnership or formal business organization of any kind.  In that respect, neither Party shall have the
authority to execute any agreement on behalf of the other Party, nor shall
either Party have any authority to negotiate any agreement, except as the other
Party may expressly direct in writing.

 

12.5        Patent Marking.  Acorda agrees to mark the appropriate patent
number or numbers on all Licensed Products made or Sold in the Licensed
Territory in accordance with all applicable governmental laws, rules and
regulations, and to requires its sublicensees to do the same.

 

13

 

12.6        Use of Names.  Acorda shall 
not use, nor shall Acorda permit sublicensees to use, the names,
trademarks, logos or symbols of Foundation or Cornell University, or their
respective employees, students and faculty members for any commercial purpose,
except as required to comply with law, regulation or court order, without the
prior written approval of Foundation. Foundation shall obtain the prior written
approval of Acorda prior to making use of the name, trademarks, logos or
symbols of Acorda for any commercial purpose, except as required to comply with
law, regulation or court order.

 

12.7        Governing Law.  This Agreement and all
amendments, modifications, alterations, or supplements hereto, and the rights
of the Parties hereunder, shall be construed under and governed by the laws of
the State of New York, U.S.A (without regard to its laws regarding choice of
law) and the United States of America. 
Only federal or state courts located in the State of New York, U.S.A.,
shall have jurisdiction to hear and decide any controversy or claim between the
Parties arising under or relating to this Agreement.

 

12.8        Entire Agreement.  This Agreement and the Appendices attached
hereto and incorporated herein constitutes the entire, final and exclusive
agreement between the Parties hereto and supercedes and terminates all prior
agreements and understandings between the Parties with respect to the subject
matter hereof.  No subsequent alteration,
amendment, change or addition to this Agreement shall be binding upon the
Parties unless reduced to writing and signed by an authorized officer of each
Party.

 

12.9        Survival.  Articles 7, 8, 9, and 12 and Section 4.6
shall survive termination of this Agreement for any reason.

 

12.10      Severability.  All rights and restrictions contained herein
may be exercised and shall be applicable and binding only to the extent that
they do not violate any applicable laws and are intended to be limited to the
extent necessary so that they will not render this Agreement illegal, invalid
or unenforceable.  If any provision or
portion of any provision of this Agreement, not essential to the commercial
purpose of this Agreement, shall be held to be illegal, invalid or
unenforceable by a court of competent jurisdiction, it is the intention of the
Parties that the remaining provisions or portions thereof shall constitute
their agreement with respect to the subject matter hereof, and all such
remaining provisions, or portions thereof, shall remain in full force and
effect.  To the extent legally
permissible, any illegal, invalid or unenforceable provision of this Agreement
shall be replaced by a valid provision which shall implement the commercial
purpose of the illegal, invalid, or unenforceable provision.  In the event that any provision essential to
the commercial purpose of this Agreement is held to be illegal, invalid or
unenforceable and cannot be replaced by a valid provision which will implement
the commercial purpose of this Agreement, the Party who is the beneficiary of
such illegal, invalid or unenforceable provision has the right to terminate
this Agreement upon written notice, effective upon receipt, to the other Party.

 

12.11      Notices.  Any notice required or permitted to be given
under this Agreement shall be in writing, shall specifically refer to this
Agreement and shall be deemed to have been sufficiently given for all purposes
if mailed by first class certified or registered mail, postage prepaid, express
delivery service or personally delivered. 
Unless otherwise specified in writing, the mailing addresess of the
Parties shall be as described below.

 

14

 

	
  For Acorda:

  	
   

  	
  Acorda Therapeutics,
  Inc.

  15 Skyline Drive

  Hawthorne, New York 10532

  Attention: Harold Safferstein

  Title: Vice President, Business Development

  
	
   

  	
   

  	
   

  
	
  For Foundation:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Payments to
  Foundation shall be sent to:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Cornell Research
  Foundation, Inc.

  20 Thornwood Drive, Suite 105

  Ithaca, NY 14850

  Attn:      Accounting

  Phone:   607-257-1081

  Fax:       607-257-1015

  
	
  All other
  communications to Foundation shall be sent to:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Cornell Research
  Foundation, Inc.

  418 E. 71st Street, Suite 61

  New York, NY 10021

  Attn:Brian J. Kelly, Vice President

  Phone:   212-746-6186

  FAX:     212-746-6662

  

 

12.12      Force Majeure.  Any delays in, or failure
of, performance of any Party to this Agreement shall not constitute a default
hereunder, or give rise to any claim for damages, if and to the extent caused
by occurrences beyond the control of the Party affected, including, but not
limited to, acts of God, acts of terrorism, strikes or other concerted acts of
workmen, civil disturbances, fires, floods, earthquakes, explosions, riots,
war, rebellion, sabotage, acts of governmental authority or failure of
governmental authority to issue licenses or approvals which may be required.

 

15

 

12.13      No Waiver.  The failure by either Party, at any time, or
for any period of time, to enforce any of the provisions of this Agreement,
shall not be construed as a waiver of such provisions or as a waiver of either
Party’s rights thereafter to enforce each and every such provision of this
Agreement.

 

12.14      Counterparts.  This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which shall
constitute one and the same instrument.

 

IN
WITNESS WHEREOF, Acorda and Foundation have caused this
Agreement to be signed, under seal, by their duly authorized representatives
below.

 

 

	
  ACORDA THERAPEUTICS,
  INC.

  	
  CORNELL RESEARCH
  FOUNDATION, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Harold T. Safferstein

  	
   

  	
  By:

  	
  /s/ Brian Kelly

  	
   

  
	
   

  	
   

  
	
  Name:

  	
  Harold T. Safferstein

  	
   

  	
  Name:

  	
  Brian Kelly

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Vice President,
  Business Development

  	
   

  	
  Title:

  	
  Vice President

  	
   

  
										

 

16

 

TABLE OF
CONTENTS

 

	
  ARTICLE
  1

  	
  DEFINITIONS

  
	
   

  	
   

  
	
  ARTICLE
  2

  	
  GRANT
  OF LICENSE

  
	
   

  	
   

  
	
  ARTICLE
  3

  	
  COMPENSATION

  
	
   

  	
   

  
	
  ARTICLE
  4

  	
  REPORTS,
  PAYMENTS AND ACCOUNTING

  
	
   

  	
   

  
	
  ARTICLE
  5

  	
  PATENTS
  AND PATENT COSTS

  
	
   

  	
   

  
	
  ARTICLE
  6

  	
  INFRINGEMENT

  
	
   

  	
   

  
	
  ARTICLE
  7

  	
  REPRESENTATIONS
  AND WARRANTIES; EXCLUSION OF WARRANTIES

  
	
   

  	
   

  
	
  ARTICLE
  8

  	
  INDEMNIFICATION;
  LIMITATION OF LIABILITY

  
	
   

  	
   

  
	
  ARTICLE
  9

  	
  CONFIDENTIALITY

  
	
   

  	
   

  
	
  ARTICLE
  10

  	
  TERM
  AND TERMINATION

  
	
   

  	
   

  
	
  ARTICLE
  11

  	
  ASSIGNMENT

  
	
   

  	
   

  
	
  ARTICLE
  12

  	
  MISCELLANEOUS

  

 

i

 

APPENDIX A - ROYALTY
REPORT

 

Report royalty payment
information to the Cornell Research Foundation, Inc (CRF) using the report
format or facsimile attached to these instructions.  This minimal information must be provided in
order to correctly record royalty related events required by your license
agreement with CRF.

 

Use a separate report to
record royalty information for each license agreement.  For each licensee agreement, report royalty
sales by CRF docket number, which identifies the technology.  List each contributing technology if more
than one technology is used to produce a royalty generating process/product.  This level of detail permits evaluation of
the use of each technology under license with your company.

 

Submit this information
along with appropriate payment to:

 

Cornell Research
Foundation, Inc.

ATTN:  Finance and Accounting

20 Thornwood Drive, Suite 105

Ithaca, NY  14850

(607) 257-1081

www.crf.cornell.edu

 

For your convenience,
payments may be made by FEDWIRE or ACH to:

Tompkins Trust Company

The Commons      

Ithaca, NY  14851

(607) 273-3210

www.tompkinstrust.com

 

Account:  01-101-007353, ABA: 021302648

 

 

ROYALTY
REPORT – [licensee NAME]

 

	
  LICENSEE NAME:

  	
  CRF LICENSE NUMBER:

  

 

REPORTING PERIOD:

 

Individual to contact
concerning this information:

 

	
  Name:

  	
  Phone # or email ID:

  

 

For each product/item
subject to a royalty payment provision, provide the following information as
applicable.

 

PRODUCT/ITEM:

 

	
  CRF Docket Number

  	
   

  	
  Country

  	
   

  	
  Number of

  Units/Products Sold

  	
   

  	
  Gross Sales By

  Country

  	
   

  	
  Net Sales By

  Country

  	
   

  	
  Royalty Rate

  	
   

  	
  Less Minimum Royalty

  Payment Made

  	
   

  	
  Net Royalty

  Payment Due

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Total Payment

  	
   

  	
   

  	
   

  

 

3Exhibit
10.16

 

Certain portions of this
Exhibit have been omitted pursuant to a request for confidentiality. Such
omitted portions, which are marked with brackets [   ] and an asterisk*, have been separately
filed with the Commission.

 

LICENSE AGREEMENT

 

THIS
LICENSE AGREEMENT (the “Agreement”) is made and entered into as of
November 12, 2002 (the “Effective Date”), by and between Acorda
Therapeutics, Inc., a corporation organized and existing under the laws of the
State of Delaware and having a principal place of business at 15 Skyline Drive,
Hawthorn, New York, USA 10532 (“Acorda”), and CeNeS Pharmaceuticals, PLC, a
corporation organized and existing under the laws of the United Kingdom and
having a principal place of business at Compass House, Vision Park, Chivers
Way, Histon, Cambridge CB4 9ZR, England (“CeNeS”).

 

WHEREAS,
CeNeS is the exclusive licensee of certain intellectual property rights
pursuant to that certain agreement, as amended, entered into by and between the
Ludwig Institute for Cancer Research (“Ludwig”) and Cambridge Neuroscience
Research, Inc. dated October 26, 1989 (the “Ludwig Agreement”);

 

WHEREAS,
CeNeS and Acorda are parties to that certain License Option Agreement dated as
of April 3, 2002, as amended, (the “License Option Agreement”), pursuant
to which CeNeS granted Acorda the option to take a sublicense of certain rights
licensed to CeNeS under the Ludwig Agreement; and

 

WHEREAS,
Acorda desires to exercise such option and to take a sublicense of such rights
as set forth herein,

 

NOW,
THEREFORE, intending to be legally bound and upon the terms, conditions and
mutual covenants hereinafter set forth, the parties agree as follows:

 

 

Part 1 - Definitions

 

1.1                                 “Affiliate” means any corporation, company, partnership,
joint venture and/or firm which controls, is controlled by, or is under common
control with a party to this Agreement. 
As used in this Paragraph, the term “control” means (a) in the case of
corporate entities, -direct or indirect ownership of at least fifty
percent (50%) of the stock or shares having the right to vote for the election
of directors, and (b) in the case of non-corporate entities, direct or indirect
ownership of at least fifty percent (50%) of the equity interest with the power
to direct the management policies of such non-corporate entities.

 

1.2                                 “Licensed Know-How” means all unpatented know-how, trade
secrets, information, data, methods, materials, techniques, reagents, cell
lines, protein sequences or segments, and monoclonal antibodies, including
without limitation, materials as described generally in Schedule B hereto,
owned or controlled by CeNeS at any time during the term of the Agreement that
is necessary or useful to practice the Patent Rights or to research, develop,
make, use or sell Licensed Products.

 

1.3                                 “Licensed Products” means Protein Products and Non-Protein
Products that are covered by one or more Valid Claims under the Patent Rights.

 

1.4                                 “Materials” means the cell lines and related biological
materials that are in CeNeS’ possession or control as of the Effective Date of
this Agreement and are directly related to the production of the protein GGF-2.

 

1.5                                 “NDA” means New Drug Application or a foreign equivalent.

 

1.6                                 “Net Sales” means the amount billed, invoiced, or received
(whichever occurs first) for Sales, leases, or other transfers of Licensed
Products, less:

 

(a)                                  customary
trade, quantity and cash discounts or rebates, and non-affiliated brokers’ or
agents’ commissions actually allowed and taken;

 

2

 

(b)                                 amounts
repaid or credited by reason of rejection, recall or return;

 

(c)                                  to
the extent separately stated on purchase orders, invoices, or other documents
of sale, taxes levied on and/or other governmental charges made as to
production, sale, transportation, delivery or use and paid by Acorda or a
Sublicensee; and

 

(d)                                 reasonable
charges for freight, packaging and insurance costs incurred in the delivery or
transportation of Licensed Products provided by third parties, if separately
stated.

 

Net
Sales also includes the fair market value of any non-cash consideration
received by Acorda or Sublicensees for the Sale, lease, or transfer of Licensed
Products.  The fair market value will be
no less than the standard selling price for the applicable Licensed Products,
each unit multiplied by the quantity of such Licensed Products delivered in
exchange for such non-cash consideration.

 

1.7                                 “Non-Protein Product” means a product that is discovered,
identified or developed through the use of material that is claimed or covered
by a Valid Claim in the Patent Rights, as a target in a screening tool or
otherwise, exclusive of Protein Products.

 

1.8                                 “Patent Rights” means the patents and patent applications
listed on Schedule A attached hereto, including without limitation, the
inventions described and/or claimed therein, and any divisionals,
continuations, continuations-in-part (to the extent that a claim of such
continuation-in-part is entitled to the priority date of at least one of the
patents or patent applications identified in Schedule A), patents issuing
thereon and reissues and reexaminations thereof, and any and all foreign
patents and patent applications corresponding thereto, all to the extent that
CeNeS has an ownership or an interest in such Patent Rights.

 

1.9                                 “Phase II Clinical Trial” means one of those trials on
sufficient numbers of subjects that are designed to establish that a
pharmaceutical product is safe and efficacious for its

 

3

 

intended
use, and to define warnings, precautions and adverse reactions that are
associated with the pharmaceutical product in the dosage range to be
prescribed.  A Phase II Clinical Trial
shall be deemed to have commenced upon the date of the first dosing of the first
subject in such trial.

 

1.10                           “Phase III Clinical Trial” means one of those trials on
sufficient numbers of subjects that are designed to establish that a
pharmaceutical product is safe and efficacious for its intended use, and to
define warnings, precautions and adverse reactions that are associated with the
pharmaceutical product in the dosage range to be prescribed, and to support
Regulatory Approval of a pharmaceutical product or label expansion of such
pharmaceutical product.  A Phase III
Clinical Trial shall be deemed to have commenced  upon the date of
the first dosing of the first subject in such trial.

 

1.11                           “Proceeds” means the royalties actually received by Acorda
from its Sublicensees for Net Sales of Licensed Products that are Non-Protein
Products.

 

1.12                           “Protein Product” means a product that is, in whole or in
part, composed of one or more proteins encoded by the growth factor gene GGF-2,
or a fragment thereof, in whatever form including any mutants, analogues,
homologues or derivative forms thereof, that is covered by a Valid Claim in the
Patent Rights.

 

1.13                           “Regulatory Approval” means the approvals, registrations or
authorizations of the United States Food and Drug Administration (the “FDA”) or successor entity, or other applicable regulatory
agency necessary for the manufacture, distribution, use or sale of a
pharmaceutical or diagnostic product in the United States or a foreign
equivalent in a major market country such as the United Kingdom, Canada, Japan
or Germany.

 

1.14                           “Sold” or “Sale” means the
sale, transfer, exchange or other commercial disposition of Licensed Products
by Acorda, its Affiliates or Sublicensees. 
In case of doubt,

 

4

 

Sales of
Licensed Products shall be deemed consummated no later than receipt of payment
from a third party for the applicable transaction involving such Licensed
Product.

 

1.15                           “Sublicense” means a grant by Acorda, either directly or
indirectly (i.e., through multiple tiers of sublicenses) to a third party of a
sublicense to practice any of the rights granted to Acorda hereunder in
accordance with this Agreement.  Such
third party shall be referred to as a “Sublicensee” under this Agreement.

 

1.16                           “Territory” means all countries and territories worldwide.

 

1.17                           “USD” means United States dollars.

 

1.18                           “Valid Claim” means (a) a pending claim of a patent
application within the Patent Rights, which (i) has been pending under
examination for less than seven (7) years, (ii) has been asserted in good
faith, and (iii) has not been abandoned or finally rejected without the
possibility of appeal or refiling; or (b) a claim of an issued, or granted and
unexpired patent within the Patent Rights, which has not been held
unenforceable, unpatentable or invalid by a decision of a court or governmental
body of competent jurisdiction, which can no longer be appealed (i.e., within
the time allowed for appeal), which has not been rendered unenforceable through
disclaimer or otherwise, which has not been abandoned, or which has not been
lost through an interference proceeding. 
A Valid Claim shall be defined as of each calendar half year ending
June 30 and December 31.

 

Part 2 - License Grant

 

2.1                                 CeNeS
hereby grants to Acorda, and Acorda accepts, an exclusive license under the
Patent Rights and Licensed Know-How to practice the same and to make, have
made, use, import, offer for sale and sell Licensed Products throughout the
Territory during the term of this Agreement.

 

5

 

Certain portions of this Exhibit have been omitted pursuant to a
request for confidentiality. Such omitted portions, which are marked with
brackets [   ] and an asterisk*, have
been separately filed with the Commission.

 

2.2                                 Acorda
hereby acknowledges that CeNeS is obligated to pay Ludwig certain royalties
with respect to Sales by Acorda and Acorda hereby agrees to be amenable to suit
by Ludwig in the event of non-payment of royalties due CeNeS hereunder by
Acorda.  If Ludwig is required to bring
suit against Acorda for any material breach of this Agreement that remains
uncured pursuant to Section 9.3(a), Acorda will pay all reasonable
out-of-pocket costs incurred by Ludwig in connection therewith, including
without limitation, reasonable attorneys fees and costs.

 

2.3                                 Acorda
shall have the right to grant sublicenses to third parties with respect to any
rights conferred upon Acorda under this Part 2, provided, however, that any
sublicense shall be subject in all respects to the conditions (e.g., payment),
restrictions, exceptions and termination provisions contained in this
Agreement.  Acorda shall provide written
notice to CeNeS within sixty(60) days of the grant of any sublicense in
accordance with this Section 2.3.

 

Part 3 - Royalties

 

3.1                                 Acorda
shall pay to CeNeS a non-refundable license fee in the sum of [**] within ten
(10) days after the Effective Date of this Agreement.

 

3.2                                 For
the license granted to Acorda hereunder, Acorda shall pay CeNeS the following
running royalties:

 

(a)                                  Acorda
shall pay to CeNeS the following running royalty based on annual Net Sales of
Protein Products by Acorda or its Affiliates:

 

	
  Annual
  Net Sales in USD

  	
   

  	
  Royalty Rate

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  [**]

  	
   

  	
  [**]

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  [**]

  	
   

  	
  [**]

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  [**]

  	
   

  	
  [**]

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  [**]

  	
   

  	
  [**]

  	
   

  

 

6

 

Certain portions of this Exhibit have been omitted pursuant to a
request for confidentiality. Such omitted portions, which are marked with
brackets [   ] and an asterisk*, have
been separately filed with the Commission.

 

(b)                                 If
Acorda is required to pay a running royalty to a third party for a license to
make, use, offer for sale, sell or import any Protein Product, then Acorda
shall have the right to offset up to [**] of such royalties actually paid to
such third party against royalties otherwise due under the foregoing Paragraph
3.2(a); provided, however, that such right of offset shall be limited such that-the
royalty due under Paragraph 3:2(b) shall not be less than [**] of annual Net
Sales of Protein Products and provided further that the amount of the offset
which is not available due to such [**] cap cannot be carried-forward for
application against future royalties due under Paragraph 3.2(a).

 

(c)                                  In
the event a Licensed Product is sold in the form of a combination product
containing one or more active ingredients in addition to the Licensed Product
active ingredient (hereinafter “Combination Licensed Product”), then Net Sales
for such Combination Licensed Product, for purposes of calculating royalties
due hereunder, will be adjusted by multiplying actual Net Sales of such
Combination Licensed Product by the applicable fraction, determined as follows:

 

(i)                                     Unless
Section 3.2(c)(ii), 3.2(c)(iii) or 3,2(c)(iv) applies below, the fraction
A/(A+B) where A is the invoice price of the Licensed Product, if sold
separately, and B is the sum of the invoice price(s) of any other active
component or components in the combination, if sold separately.

 

(ii)                                  If,
on a country-by-country basis, the other active component or components in the
Combination Licensed Product are not sold separately in said country, the

 

7

 

Certain portions of this Exhibit have been omitted pursuant to a
request for confidentiality. Such omitted portions, which are marked with
brackets [   ] and an asterisk*, have been separately filed
with the Commission.

 

fraction shall be A/C where A is the invoice price of
the Licensed Product if sold separately, and C is the invoice price- of the
Combination Licensed Product.

 

(iii)                               If,
on country by-country basis, the Licensed Product is not sold separately in
said country, the fraction shall be [1-(B/C)] where B is the invoice price sum
of any other active components or components in the combination, if sold
separately and C is the invoice price of the Combination Licensed Product.

 

(iv)                              If,
on a country-by-country basis, neither the Licensed Product nor the other
active component or components of the Combination Licensed Product is sold
separately in said country, the fraction shall be negotiated in good faith by
the parties with the intention of agreeing upon a fair and equitable formula
that reasonably reflects the relative value contributed by the Licensed Product
to the total value of the combination in the Combination; Licensed
Product, as compared to the other active ingredients therein.

 

(d)                                 Acorda
shall pay to CeNeS a royalty of [**] of annual Net Sales of Protein Products by
Sublicensees.

 

(e)                                  Acorda
shall pay to CeNeS a royalty of [**] of annual Net Sales by Acorda of
Non-Protein Products, and [**] of the Proceeds actually received by Acorda from
its Sublicensees on their Sales of Non-Protein Products.

 

(f)                                    Minimum
Annual Royalty.  To the extent that
cumulative annual royalties paid to CeNeS with respect to each Licensed Product
during any calendar year, commencing with the third calendar year following
first commercial sale of any Licensed Product, are less than [**], a minimum
annual royalty with respect to such Licensed Product in the amount of such
shortfall shall be payable by Acorda.  If
Acorda fails to pay any such minimum royalty for a Licensed Product, CeNeS
shall have the option of converting the

 

8

 

Certain portions of this Exhibit have been omitted pursuant to a
request for confidentiality. Such omitted portions, which are marked with
brackets [   ] and an asterisk*, have
been separately filed with the Commission.

 

license
or any sublicense granted hereunder with respect to such Licensed Product to a
nonexclusive license by giving Acorda written notice thereof.

 

3.3                                 Acorda
shall pay to CeNeS the following non-refundable milestone payments for every
Protein Product in respect of which Acorda, an Affiliate or Sublicensee
achieves any or all of the milestone events indicated below.  Should a Protein Product be abandoned by
Acorda, Its Affiliate or Sublicensee for any reason following completion of any
of the first five milestones but prior to the Approval of a NDA and Acorda
commences development of a subsequent Protein Product, then Acorda shall resume
the milestone payments for such subsequent Protein Product starting at the
event subsequent to the event for which a milestone payment had already been
paid.  Each such milestone payment shall
be paid within thirty (30) days of the achievement of the relevant milestone
event.  For clarity, each milestone
payment shall be paid only once for each Protein Product and Acorda shall pay
milestones on a Protein Product only if its active pharmaceutical ingredient
(the “API”), is different from the API of any other Protein Product for which
Acorda has already made milestone payments.

 

	
  Milestone
  Event

  	
   

  	
  Milestone Payment

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Satisfactory
  completion of animal toxicology studies necessary to enter into Phase I
  clinical studies in accordance with the International Conference of
  Harmonization (ICH) guidelines provided by the US Food and Drug
  Administration*

  	
   

  	
  $

  	
  [**]

  	
   

  
	
  Issuance
  of an Investigational New Drug Application (or foreign equivalent**)

  	
   

  	
  $

  	
  [**]

  	
   

  
	
  Enrollment
  of the first subject in a Phase II clinical trial (or foreign equivalent**)

  	
   

  	
  $

  	
  [**]

  	
   

  
	
  Enrollment
  of the first subject in a Phase III clinical trial (or foreign equivalent**)

  	
   

  	
  $

  	
  [**]

  	
   

  
	
  Filing
  of a New Drug Application (or foreign equivalent**)

  	
   

  	
  $

  	
  [**]

  	
   

  
	
  Approval
  of a New Drug Application (or foreign equivalent**)

  	
   

  	
  $

  	
  [**]

  	
   

  

 

*            “Completion
of animal toxicology studies” shall mean the completion of all analysis of data
generated in such study and delivery of the final report thereon.

 

**     “Foreign
equivalent” shall mean the completion of the milestones in a foreign major
market country such as the United Kingdom, Japan, Germany, Canada, etc.

 

9

 

3.4                                 (a)                                  All
amounts due hereunder shall be payable in United States Dollars.  Royalty payments shall be made within sixty
(60) days following the end of each calendar quarter.  Each such payment shall include royalties
which shall have accrued during the calendar quarter immediately preceding and
shall be accompanied by a report setting forth separately the Net Sales of all
Licensed Products sold during said calendar quarter.  Any royalty payment required to be made to
CeNeS under Paragraph 3.2(e) shall be made in U.S. Dollars on or before
January 31st of following the calendar year to which such payment relates.

 

(b)                                 Royalties
shall be payable only once (at the highest -applicable rate) with
respect to the same unit of Licensed Product regardless of the number of claims
of Patent tights pertaining to same. 
Royalties shall apply to any Sale of Licensed Product to, a
third party from which Acorda, its Affiliate or Sublicensee derives
revenue.  On any transfer or disposal of
Licensed Product among Acorda, its Affiliates or Sublicensees, royalties shall
become payable only upon further transfer to a third party.

 

(c)                                  The
remittance of royalties payable on the Net Sales of Licensed Product outside
the U.S. shall be made to CeNeS in U.S. Dollars a the official rate of exchange
of the currency of the country from which the royalties are payable (as quoted
by Citibank N.A. for the last business day of the calendar quarter in which the
royalties are payable) less any withholding or transfer taxes which are
applicable.  Acorda or a Sublicensee
shall supply CeNeS with proof of payment of such taxes paid on CeNeS’s behalf and
shall cooperate with CeNeS in obtaining credit or refund of any such taxes.

 

10

 

(d)                                 No
royalties for Sales outside the U.S. shall be payable with respect to any Sales
as to which conversion cannot be made of the currency billed in U.S. Dollars
until such conversion can be legally made, at which time royalties shall be
paid in U.S. Dollars at the rate of exchange quoted by Citibank, N.A., for the
business day immediately preceding the date on which the restriction on
conversion was lifted.  However, CeNeS
shall have the right to have the royalties payable by Acorda, its Affiliates or
Sublicensees deposited in CeNeS’s name in the blocked currency in an interest
bearing account in a bank designed by CeNeS in the foreign country in
question.  In the event CeNeS cannot
arrange to have the blocked currency transferred out of the foreign country
within twelve (12) months after deposit, CeNeS shall notify Acorda in writing
and Acorda shall as soon as possible thereafter cause such royalties (plus
earnings thereon during the period of deposit) to be paid to CeNeS in U.S.
Dollars at the rate of exchange quoted by Citibank, N.A. on the day the blocked
currency was deposited in the bank designated by CeNeS.  Upon receipt of the payment, CeNeS shall
release to Acorda from the bank in the foreign country in question the blocked
currency in accordance with Acorda’s instructions.

 

(e)                                  Acorda,
its Sublicensees and Affiliates shall keep and maintain records of sales of
Licensed Products for a period of three (3) years after the royalty period to
which such records relate.  Such records
shall be open to inspection upon at least fifteen (15) business days’ prior
written notice at any reasonable time during normal business hours not more
often than once each calendar quarter by an independent Certified Public
Accountant selected by CeNeS, to whom Acorda or, if applicable, its Affiliates
or Sublicensees, have no reasonable objection, who shall have the right to
examine and make abstracts of the records kept pursuant to this Agreement and
report findings of said examination of records to CeNeS insofar as it is
necessary to evidence any mistake or impropriety on the part of Acorda.  Said independent Certified Public Accountant

 

11

 

shall
treat as confidential and shall not use or disclose to any third party any
information acquired during the course of such examination, except information
which shall be made available to CeNeS or Ludwig pursuant to any provision of
this Agreement.

 

(f)                                    Acorda’s
obligation to pay royalties with respect to Net Sales of Licensed Product in my
country shall continue for so long as CeNeS owns or holds exclusive rights to a
valid and enforceable issued patent within the Patent Rights covering such
Licensed Product in Such country.  If
Acorda’s obligation to pay royalties is based solely on the practice of the
Patent Rights to discover or develop a Non-Protein Product, said obligation
shall continue until fifteen (15) years from the Effective Date of this
Agreement.

 

Part 4 - Patent Matters

 

4.1                                 Upon
execution of this Agreement, Acorda shall assume responsibility and control, at
its expense, during the Term for the preparation, filing, prosecution and
maintenance of any and all patent applications and patents included in Patent
Rights.  Notwithstanding the previous
sentence, Acorda shall furnish to CeNeS copies of all material documents
pertaining to such preparation, filing, prosecution or maintenance, including
filings and correspondence with patent authorities, in a timely manner, so as
to give CeNeS an opportunity to comment thereon and Acorda shall use good faith
efforts to accommodate any such comments.

 

4.2                                 Ludwig,
CeNeS, and Acorda shall cooperate fully in the preparation, filing, prosecution
and maintenance of Patent Rights and of all patents and patent applications
licensed to Acorda hereunder, executing all papers and instruments or requiring
members of Ludwig and/or CeNeS to execute such papers and instruments so as to
enable Acorda to apply for, to prosecute and to maintain patent applications
and patents in Ludwig’s name in any country. 
Each party shall provide to the other prompt notice as to all matters
which come to its attention

 

12

 

and
which may affect the preparation, filing, prosecution or maintenance of any
such patent applications or patents.

 

4.3                                 Acorda
may elect to surrender its rights under the Patent Rights on a patent-by-patent
basis in any country upon sixty (60) days written notice to CeNeS.  CeNeS may elect thereafter to continue
prosecution and maintenance of such patents at its own expense.

 

Part 5 - Patent Infringement

 

5.1                                 Enforcement
by Acorda.  If either CeNeS or Acorda
becomes aware of a product made, used or sold in the Territory, or any other
activities, which it believes infringes a Valid Claim, the party obtaining such
knowledge shall promptly advise the other patty of all relevant facts and
circumstances pertaining to the potential infringement.  Acorda shall have the first right, but not
the obligation, to enforce any patent rights against such infringement, at its
own expense.  CeNeS and Ludwig shall cooperate
with Acorda in such effort, at Acorda’s expense, including being joined as a
party to such action, if necessary.  Any
damages or costs recovered in connection with any action filed by Acorda
hereunder which exceed Acorda’s out-of-pocket costs and expenses of litigation,
shall be deemed to be Net Sales of Protein Products in the fiscal quarter
received by Acorda, and royalties shall be payable by Acorda to CeNeS thereon
in accordance with the terms of this Agreement.

 

5.2                                 Backup
Enforcement Right by CeNeS.  If Acorda
fails within one hundred twenty (120) days after receiving notice from CeNeS of
a potential infringement, or providing CeNeS with notice of such infringement,
to either (a) terminate such infringement or (b) institute an action to prevent
continuation thereof and, thereafter to prosecute such action diligently, or if
Acorda notifies CeNeS that it does not plan to terminate the infringement or
institute such action, then CeNeS shall have the right to do so at its own
expense; provided however, that CeNeS first

 

13

 

consults
with Acorda and gives due consideration to Acorda’s reasons for not instituting
actions to terminate or otherwise prevent continuation of such
infringement.  If CeNeS decides to pursue
such infringement, Acorda shall cooperate with CeNeS in such effort including
being joined as a party to such action if necessary.  CeNeS shall be entitled to retain all damages
or costs awarded to CeNeS in such action.

 

5.3                                 In
the event that Acorda, its Affiliate or Sublicensee is sued by a third party
charging infringement of a patent resulting from the manufacture, use or sale
by Acorda, its Affiliate or Sublicensee of a Licensed Product, Acorda shall
promptly notify CeNeS.  During the period
in which any such suit is pending, Acorda shall have the right to apply up to
fifty percent (50%) of the royalties due CeNeS against Acorda’s litigation
expenses of any such suit.

 

Part 6 - Diligence

 

6.1                                 Acorda
agrees to use all reasonable efforts to effect introduction of Licensed
Products into the commercial market as soon as practicable, consistent with
sound and reasonable business practices and judgment.

 

Part 7 - Indemnification and
Insurance

 

7.1                                 Acorda
hereby indemnifies CeNeS, Ludwig and their respective directors, officers,
employees and agents (collectively, the “CeNeS Indemnitees”)
and agrees to be solely responsible and to hold CeNeS Indemnitees harmless from
any third party claim, demands, suits or causes of action, including all
judgments, damages, and costs (including reasonable attorneys’ fees) resulting
therefrom, arising out of the use, manufacture, sale, storage or advertising of
any Licensed Product except to the extent of such judgments, damages and costs
that arise from the negligence or willful misconduct of CeNeS Indemnitees.

 

14

 

7.2                                 CeNeS
hereby indemnifies Acorda, its Affiliates, directors, officers, agents,
contractors, Sublicensees and employees (collectively, the “Acorda Indemnitees”) and agrees to be solely responsible and
to hold Acorda Indemnitees harmless from any third party claim demands, suits
or causes of action, including all judgments, damages, and costs (including
reasonable attorneys’ fees) resulting therefrom, arising out of any breach of
Section 8.1 except to the extent of such judgments, damages and costs that
arise from the negligence or willful misconduct of Acorda Indemnitees.

 

7.3                                 To
be eligible to be indemnified hereunder, the indemnified party shall provide
the indemnifying party with prompt notice of the claim giving rise to the indemnification
obligation pursuant to this Part 7 and the exclusive ability to defend (with
the reasonable cooperation of the indemnified party) or settle any such claim; provided, however, that the indemnifying party shall not
enter into any-settlement for damages other than monetary damages without the
indemnified party’s written consent, such consent not to be unreasonably
withheld or delayed.  The indemnified
party shall have the right to participate, at its own expense and with counsel
of its choice, in the defense of any claim or suit that has been assumed by the
indemnifying party.

 

7.4                                 Prior
to commencing human use of any Licensed Product hereunder, Acorda shall obtain
and maintain thereafter comprehensive general liability insurance (to include
advertisers’ liability and product liability) written by a reputable insurer or
insurers approved by CeNeS and shall list CeNeS as an additional named insured
thereunder and shall require thirty (30) days written notice to be given to
CeNeS prior to any cancellation or material change thereof.  The limits for such insurance shall not be
less than ten million dollars (USD 10,000,000) per occurrence for personal
injury and property damage, adjusted for inflation every year based on

 

15

 

the U.S.
Consumer Price Index in effect on the first day of such year.  Acorda shall provide CeNeS with certificates
of insurance evidencing the same upon written request by CeNeS.

 

Part 8 - Representations and
Warranties

 

8.1                                 CeNeS
Representations and Warranties.  CeNeS
represents and warrants that:

 

(a)                                  its
obligations under this Agreement are not in conflict with any prior commitments
or obligations to any third party; that it has all requisite power and
authority to enter into this Agreement; and that all corporate action necessary
to authorize its execution and delivery of this Agreement has been duly taken;

 

(b)                                 it
has the right to grant the rights granted in this Agreement and perform the
obligations set forth herein;

 

(c)                                  it
and its Affiliates have not granted to any third party any license, option or
other rights under the Patent Rights, and to its knowledge, the Ludwig License
is in full force and effect;

 

(d)                                 to
its knowledge, there are no facts or circumstance which would render any of the
Patent Rights invalid or unenforceable;

 

(e)                                  to
its knowledge, there is no interference action, opposition, reissue or
reexamination proceeding, or any intellectual property litigation pending
before any patent office or court concerning any of the Patent Rights; and

 

(f)                                    Cambridge
Neuroscience Research, Inc. has assigned all its rights and obligations in the
Ludwig Agreement to CeNeS.

 

8.2                                 Acorda
Representations and Warranties.  Acorda
represents and warrants that its obligations under this Agreement are not in
conflict with any prior commitments or obligations to any third party; that it
has all requisite power and authority to enter into this Agreement; and

 

16

 

that all
corporate action necessary to authorize its execution and delivery of this
Agreement has been duly taken.

 

Part 9 - Term and Early
Termination

 

9.1                                 Unless
sooner terminated as herein provided, this Agreement shall continue in full
force and effect commencing on the Effective bate of this Agreement and
continuing until the later of fifteen (15) years thereafter or the expiration
of the last-to-expire Valid Claim in the Patent Rights.

 

9.2                                 Acorda
may terminate this Agreement at any time for any reason, upon thirty (30) days
prior written notice to CeNeS.

 

9.3                                 (a)                                  A
party may terminate this Agreement and the license herein granted upon the
breach of any material obligation herein by the other party upon sixty (60)
days written notice; provided that if during such sixty (60) day period the
party so notified cures such material breach, then this Agreement shall
continue in full force and effect.

 

(b)                                 If
this Agreement is terminated as provided in Paragraphs 9.2 or 9.3(a), Acorda
shall promptly make an accounting to CeNeS of the inventory of Licensed
Products which it and its Affiliates and Sublicensees have on hand as of the
effective date of such termination, if applicable.  Acorda, its Affiliates and Sublicensees shall
then have the right, for a period of six (6) months after said termination, to
sell such inventory provided that the Net Sales thereof shall be subject to the
royalty rates payable to CeNeS as set forth above.

 

9.4                                 The
license to Acorda set forth in Section 2.1 shall continue after any
termination or expiration of this Agreement as set forth in this
Section 9.4.  If this Agreement
expires pursuant to Section 9.1, then Acorda shall thereafter retain a
nonexclusive, perpetual, royalty-free, worldwide license, with the full right
to sublicense, under the Patent Rights and Licensed

 

17

 

Know-How
to practice such technology and rights for all purposes.  If this Agreement is terminated by Acorda
pursuant to Section 9.3, then Acorda, in its sole discretion, may elect to
retain the exclusive license granted in Section 2.1, subject to the
payment of the royalties otherwise due under Section 3.2.

 

Part 10 - Confidentiality

 

10.1                           Treatment
of Confidential Information.  Except as
otherwise provided hereunder, during the term of this Agreement and for a
period of five (5) years thereafter:

 

(a)                                  CeNeS,
its Affiliates and Sublicensees shall retain in confidence and use only for
purposes of this Agreement, any written information and data supplied by Acorda
to CeNeS under this Agreement and marked as proprietary or confidential; and

 

(b)                                 Acorda
shall retain in confidence and use only for purposes of this Agreement, any
written information and data supplied by CeNeS to Acorda under this Agreement
and marked as proprietary or confidential.

 

For purposes
of this Agreement, all such information and data which a party is obligated to
retain in confidence shall be called “Information.”  Any written information, materials or data
relating to GGF-2 disclosed by one party to the other party pursuant to the
License Option Agreement and the Confidentiality Agreement entered into as of
July 23, 2001 shall be deemed Information under this Agreement.

 

10.2                           Permitted
Disclosure.  To the extent that it is
reasonably necessary to fulfill its obligations or exercise its rights under
this Agreement, or any rights which survive termination or expiration hereof,
each party may disclose Information to its Affiliates, sublicensees,
consultants, outside contractors and clinical investigators on condition that
such entities or persons agree:

 

18

 

(a)                                  to
keep the Information confidential for at least the same time periods and to the
same extent as each party is required to keep the Information confidential and

 

(b)                                 to
use the Information only for such purposes as such parties are authorized to
use the Information.

 

Each
party, its Affiliates or sublicensees may disclose Information to regulatory
authorities to the extent that such disclosure is necessary for the prosecution
and enforcement of patents, authorizations to conduct clinical trials or
commercialization of Licensed Products, provided that such party is otherwise
entitled to engage in such activities under this Agreement.  Each party, its Affiliates or sublicensees
may disclose Information to the government or a court of competent
jurisdiction, provided that such disclosing party (a) provides the other party
with adequate notice of the required disclosure, (b) cooperates with the other
party’s efforts to protect its Information with respect to such disclosure and
(c) takes all reasonable measures requested by the other party to challenge or
to modify the scope of such required disclosure.  CeNeS may disclose Information to Ludwig to
the extent such disclosure is required pursuant to CeNeS’ obligations under the
Ludwig Agreement.

 

10.3                           The
obligation under Section 10.1 not to use or disclose Information shall not
apply to any part of such Information that the recipient party can establish by
competent written proof:

 

(a)                                  is
or becomes patented, published or otherwise part of the public domain, other
than by unauthorized acts of the party obligated not to disclose such
Information (for purposes of this Part 10 (the “Receiving
Party”), its Affiliates or Sublicensees in contravention of this
Agreement;

 

19

 

(b)                                 is
disclosed to the Receiving Party, its Affiliates or Sublicensees by a third
party provided that such Information was not obtained by such third party
directly or indirectly from the other party under this Agreement;

 

(c)                                  prior
to disclosure under this Agreement, was already in the possession of the
Receiving Party, its Affiliates or Sublicensees, provided that such Information
was not obtained directly or indirectly from the other patty under this
Agreement;

 

(d)                                 results
from the research and development by the Receiving Party, its Affiliates or
Sublicensees, independent of disclosures from the other party of this
Agreement, provided that the persons developing such information have not had
exposure to the Information received from the disclosing party; or

 

(e)                                  CeNeS
and Acorda agree in writing may be disclosed.

 

10.4                           Confidential
Nature of the Terms of Agreement.  Except
as expressly provided herein, CeNeS and Acorda each agrees not to disclose any
terms of this Agreement to any third party without the consent of the other
party; provided, however, that disclosures may be made as required by
securities or other applicable laws, or to actual or prospective investors or
corporate partners, or to a party’s accountants, attorneys, and other
professional advisors who agree to appropriate confidentiality provisions to
protect such terms from disclosure or improper use.

 

Part 11 - General Provisions

 

11.1                           Except
as required by law, neither CeNeS nor Acorda shall originate any publicity,
news release, or other public announcement, written or oral, whether to the
public press, to stockholders, or otherwise, relating to this Agreement to any
amendment thereto or to performance hereunder or the existence of an
arrangement between the parties without the prior written approval of the other
party, not to be unreasonably withheld; provided that, no such

 

20

 

consent
shall be required for non-public communications between Acorda and its current,
or potential stockholders, investors, acquiring parties, merger partners or
Sublicensees.  Acorda shall not use the
name Ludwig, or CeNeS (or any variant thereof) or any related organization in
any advertising, packaging (except for customary technical references) or other
promotional material in connection with the sale of Licensed Products referred
to in this Agreement.

 

11.2                           Acorda
acknowledges that it has certain duties and obligations under Part 379 of the
Export Administration Regulations of the U.S. Department of Commerce (as
presently promulgated or hereafter modified or amended) concerning the export
and reexport of technical data.  Acorda
will be solely responsible for any breach of such Regulations by Acorda, its
Affiliates or Sublicensees and will defend and hold Indemnitees harmless in the
event of a suit or action involving any such breach.

 

11.3                           Neither
party may assign or transfer this Agreement or any rights or obligations
hereunder without the prior written consent of the other, such consent not to
be unreasonably withheld, and except that a party may make such an assignment
without the other party’s consent to an Affiliate or to a successor to all, or
substantially all, of the business and assets to which this Agreement relates
of such party, whether in a merger, sale of stock, sale of assets or other
transaction of the division or divisions of Acorda involved in the development
and sale of Licensed Products.  Any
permitted successor or assignee of rights and/or obligations hereunder shall,
in a writing to the other party, expressly assume performance of such rights
and/or obligations.  Any permitted
assignment shall be binding on the successor of the assigning party.

 

11.4                           All
notices required to be given by one party to the other hereunder shall be
sufficient if signed by such party (or such party’s attorney) and either:  (a) delivered in person; (b) mailed certified
mail, postage prepaid, return receipt requested; or (b) faxed to the other
party

 

21

 

provided
that the sender receives acknowledgement that such notice has been received by
the party to be notified and promptly sends the original by ordinary mail; in
any event, to the following addresses:

 

	
  If to Acorda:

  
	
   

  
	
   

  	
  Acorda Therapeutics,
  Inc,

  
	
   

  	
  15 Skyline Drive

  
	
   

  	
  Hawthorne, NY 10532

  
	
   

  	
  Attn: President and
  Chief Executive Officer

  
	
   

  	
   

  
	
  with a copy to:

  
	
   

  	
   

  
	
   

  	
  Acorda Therapeutics,
  Inc.

  
	
   

  	
  15 Skyline Drive

  
	
   

  	
  Hawthorne, NY 10532

  
	
   

  	
  Attn: Harold Safferstein,
  Vice President, Business Development

  
	
   

  	
   

  
	
  If to CeNeS:

  
	
   

  	
   

  
	
   

  	
  CeNeS Pharmaceuticals
  plc

  
	
   

  	
  Compass House

  
	
   

  	
  Vision Park

  
	
   

  	
  Clovers Way

  
	
   

  	
  Histon, Cambridge CI4
  9ZR

  
	
   

  	
  England

  
	
   

  	
  Attn: Neil Clark, Chief
  Operating Officer and Finance Director

  

 

By
such notice either party may change their address for future notices.  Notices delivered in person shall be deemed
given on the date delivered.  Notices
sent by fax shall be deemed given on the date faxed.  Notices mailed shall be deemed given two (2)
days after the date postmarked on the envelope.

 

11.5                           This
Agreement constitutes the entire agreement between the parties and supersedes
all written or oral prior agreements or understandings with respect to the
subject matter hereof except that any confidential information disclosed
pursuant to the License Option

 

22

 

Agreement
shall be deemed Information of this Agreement. 
No variation or modification of the terms or provisions of this
Agreement shall be valid unless in writing and signed by the patties hereto.

 

11.6                           No
right or license is granted by CeNeS under this Agreement to Acorda, or by
Acorda to CeNeS, either expressly or by implication, except those specifically
set forth herein.

 

11.7                           Waiver
by Acorda or CeNeS of any single default or breach or succession of defaults or
breaches by the other shall not deprive CeNeS or Acorda of any right to
terminate this Agreement arising out of any subsequent default or breach nor
shall it be construed as a waiver of either party’s rights thereafter to
enforce each and every provision of this Agreement.

 

11.8                           All
matters affecting the interpretation, validity, and performance of this
Agreement shall be governed by the laws of the State of New York applicable to
agreements made and to be performed wholly within New York, but the scope and
validity of Patent Rights shall be governed by the applicable laws of the
country granting the patent in question.

 

11.9                           Acorda’s
relationship with CeNeS shall be that of a licensee only.  Neither party shall be considered to be an
employee or agent of the other, nor shall this Agreement constitute, create or
in any way be interpreted as a joint venture, partnership or formal business
organization of any kind.  In that
respect, neither party shall have the authority to execute any agreement on
behalf of the other party, nor shall either party have any authority to
negotiate any agreement, except as the other party may expressly direct in
writing.

 

11.10                     Parts 7, 8,
and 10 and Sections 9.3(b), 9.4 and 11.10 shall survive termination of this
Agreement for any reason.

 

11.11                     This
Agreement may be executed in one or more counterparts, each of which shall be
deemed an original, but all of which shall constitute one and the same
instrument.

 

23

 

11.12                     The captions
herein are solely for convenience of reference and shall not affect the
construction or interpretation of this Agreement.

 

IN
WITNESS WHEREOF, CeNeS and Acorda have caused this Agreement to be executed in
duplicate by their respective duty authorized officers.

 

 

	
  CeNeS
  PHARMACEUTICALS, PLC

  	
  ACORDA
  THERAPEUTICS, INC.

  
	
   

  	
   

  
	
  By:

  	
  /s/ Neil Clark

  	
   

  	
  By:

  	
  /s/ Harold T.
  Safferstein

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Print Name:

  	
  Neil Clark

  	
   

  	
  Print Name:

  	
  Harold T.
  Safferstein

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Finance Director

  	
   

  	
  Title:

  	
  VP Business
  Development

  	
   

  
												

 

24

 

SCHEDULE A

 

PATENT RIGHTS

 

Granted Patent List

 

	
  Matter

  Number

  	
   

  	
  Country

  	
   

  	
  Patent

  Number

  	
   

  	
  Grant

  Date

  	
   

  	
  Filing

  Date

  	
   

  	
  Status

  	
   

  	
  Inventors

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002AU5

  	
   

  	
  Australia

  	
   

  	
  688270

  	
   

  	
  02-Jul-1998

  	
   

  	
  29-Jun-1993

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002AU6

  	
   

  	
  Australia

  	
   

  	
  709968

  	
   

  	
  23-Dec-1999

  	
   

  	
  25-May-1995

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002AUX

  	
   

  	
  Australia

  	
   

  	
  703772

  	
   

  	
  15-Jul-1999

  	
   

  	
  09-Oct-1996

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002EP1

  	
   

  	
  Europe

  	
   

  	
  0579640

  	
   

  	
  24-Jul-2002

  	
   

  	
  03-Apr-1992

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002KR1

  	
   

  	
  Korea

  	
   

  	
  274305

  	
   

  	
  08-Sep-2000

  	
   

  	
  03-Apr-1992

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002KR5

  	
   

  	
  Korea

  	
   

  	
  307943

  	
   

  	
  25-Aug-2001

  	
   

  	
  29-Jun-1993

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002KR6

  	
   

  	
  Korea

  	
   

  	
  265928

  	
   

  	
  09-Jun-2000

  	
   

  	
  25-May-1995

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002KR7

  	
   

  	
  Korea

  	
   

  	
  297680

  	
   

  	
  24-May-2001

  	
   

  	
  25-May-1995

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002KR8

  	
   

  	
  Korea

  	
   

  	
  344006

  	
   

  	
  28-Jun-2002

  	
   

  	
  29-Jun-1993

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002PT1

  	
   

  	
  Portugal

  	
   

  	
  100344

  	
   

  	
  02-May-1999

  	
   

  	
  03-Apr-1992

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002PT5

  	
   

  	
  Portugal

  	
   

  	
  101297

  	
   

  	
  07-Jul-1999

  	
   

  	
  30-Jun-1993

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002005

  	
   

  	
  United States

  	
   

  	
  5,530,109

  	
   

  	
  25-Jun-1996

  	
   

  	
  24-Mar-1993

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002006

  	
   

  	
  United States

  	
   

  	
  5,716,930

  	
   

  	
  10-Feb-1998

  	
   

  	
  26-May-1994

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002007

  	
   

  	
  United States

  	
   

  	
  5,621,081

  	
   

  	
  15-Apr-1997

  	
   

  	
  06-Jun-1995

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  

 

 

	
  Matter

  Number

  	
   

  	
  Country

  	
   

  	
  Patent

  Number

  	
   

  	
  Grant

  Date

  	
   

  	
  Filing

  Date

  	
   

  	
  Status

  	
   

  	
  Inventors

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002009

  	
   

  	
  United States

  	
   

  	
  5,606,032

  	
   

  	
  25-Feb-1997

  	
   

  	
  06-Jun-1995

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J. Goodearl
  et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200A

  	
   

  	
  United States

  	
   

  	
  5,792,849

  	
   

  	
  11-Aug-1998

  	
   

  	
  06-Jun-1995

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200G

  	
   

  	
  United States

  	
   

  	
  5,602,096

  	
   

  	
  11-Feb-1997

  	
   

  	
  06-Jun-1995

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200J

  	
   

  	
  United States

  	
   

  	
  6,204,241

  	
   

  	
  20-Mar-2001

  	
   

  	
  22-Oct-1996

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200L

  	
   

  	
  United States

  	
   

  	
  6,194,377

  	
   

  	
  27-Feb-2001

  	
   

  	
  22-Oct-1996

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200P

  	
   

  	
  United States

  	
   

  	
  5,854,220

  	
   

  	
  29-Dec-1998

  	
   

  	
  22-Oct-1996

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002ZA1

  	
   

  	
  South Africa

  	
   

  	
  92/2001

  	
   

  	
  25-Nov-1992

  	
   

  	
  01-Apr-1992

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002ZA5

  	
   

  	
  South Africa

  	
   

  	
  93/4711

  	
   

  	
  31-Aug-1994

  	
   

  	
  30-Jun-1993

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-039AU1

  	
   

  	
  Australia

  	
   

  	
  713384

  	
   

  	
  16-Mar-2000

  	
   

  	
  27-Mar-1996

  	
   

  	
  Granted

  	
   

  	
  Thomas A. Reh et
  al.

  
	
  Title:  METHODS OF TREATING DISORDERS OF THE EYE

  

 

	
  Matter

  Number

  	
   

  	
  Patent

  Country

  	
   

  	
  Grant

  Number

  	
   

  	
  Grant

  Date

  	
   

  	
  Filing

  Date

  	
   

  	
  Status

  	
   

  	
  Inventors

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-04AU1

  	
   

  	
  Australia

  	
   

  	
  707599

  	
   

  	
  28-Oct-1999

  	
   

  	
  16-Nov-1995

  	
   

  	
  Granted

  	
   

  	
  David I. Gwynne
  et al.

  
	
  Title:  USE OF NEUREGULIN AS MODULATORS OF CELLULAR
  COMMUNICATION

  
	
   

  
	
  04585-041001

  	
   

  	
  United States

  	
   

  	
  6,087,323

  	
   

  	
  11-Jul-2000

  	
   

  	
  17-Nov-1994

  	
   

  	
  Granted

  	
   

  	
  David I. Gwynne
  et al.

  
	
  Title: USE OF
  NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION

  
	
   

  
	
  04585-043AU2

  	
   

  	
  Australia

  	
   

  	
  727037

  	
   

  	
  15-Mar-2001

  	
   

  	
  12-Nov-1996

  	
   

  	
  Granted

  	
   

  	
  Mark Marchionni
  et al.

  
	
  Title:  METHODS OF TREATING DISORDERS OF NON-VISUAL
  SENSORY EPITHELIA

  
	
   

  
	
  04585-048AU2

  	
   

  	
  Australia

  	
   

  	
  745324

  	
   

  	
  21-Mar-2002

  	
   

  	
  08-Oct-1998

  	
   

  	
  Natl Phase

  	
   

  	
  R. McBurney et
  al.

  
	
  Title:  THERAPEUTIC METHODS COMPRISING USE OF A
  NEUREGULIN

  
	
   

  
	
  04585-051001

  	
   

  	
  United States

  	
   

  	
  5,594,114

  	
   

  	
  14-Jan-1997

  	
   

  	
  17-Aug-1992

  	
   

  	
  Granted

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  SCHWANN CELL MITOGENIC FACTOR, ITS
  PREPARATION AND USE

  

 

2

 

Pending
Patent Application List

 

	
  Matter

  Number

  	
   

  	
  Country

  	
   

  	
  Application

  Number

  	
   

  	
  Filing

  Date

  	
   

  	
  Status

  	
   

  	
  Inventors

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002CA1

  	
   

  	
  Canada

  	
   

  	
  2,108,199

  	
   

  	
  03-Apr-1992

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002CA5

  	
   

  	
  Canada

  	
   

  	
  2,139,136

  	
   

  	
  29-Jun-1993

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002CA6

  	
   

  	
  Canada

  	
   

  	
  2,191,085

  	
   

  	
  25-May-1995

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002CN6

  	
   

  	
  China

  	
   

  	
  95 1 9320X

  	
   

  	
  25-May-1995

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002EP5

  	
   

  	
  Europe

  	
   

  	
  93 918139.2

  	
   

  	
  29-Jun-1993

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002EP6

  	
   

  	
  Europe

  	
   

  	
  95922145.8

  	
   

  	
  25-May-1995

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002IE1

  	
   

  	
  Ireland

  	
   

  	
  921062

  	
   

  	
  03-Apr-1992

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002MX6

  	
   

  	
  Mexico

  	
   

  	
  965812

  	
   

  	
  25-May-1995

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002PH5

  	
   

  	
  Philippines

  	
   

  	
  44157

  	
   

  	
  03-Apr-1992

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002008

  	
   

  	
  United States

  	
   

  	
  08/470,339

  	
   

  	
  06-Jun-1995

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200E

  	
   

  	
  United States

  	
   

  	
  08/469,549

  	
   

  	
  06-Jun-1995

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200F

  	
   

  	
  United States

  	
   

  	
  08/471,833

  	
   

  	
  06-Jun-1995

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200H

  	
   

  	
  United States

  	
   

  	
  08/472,065

  	
   

  	
  06-Jun-1995

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200I

  	
   

  	
  United States

  	
   

  	
  08/734,665

  	
   

  	
  22-Oct-1996

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200M

  	
   

  	
  United States

  	
   

  	
  08/735,010

  	
   

  	
  13-May-1999

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J. Goodearl
  et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  

 

3

 

	
  Matter

  Number

  	
   

  	
  Country

  	
   

  	
  Application

  Number

  	
   

  	
  Filing

  Date

  	
   

  	
  Status

  	
   

  	
  Inventors

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200N

  	
   

  	
  United States

  	
   

  	
  08/736,070

  	
   

  	
  22-Oct-1996

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200Q

  	
   

  	
  United States

  	
   

  	
  08/736,019

  	
   

  	
  22-Oct-1996

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-00200R

  	
   

  	
  United States

  	
   

  	
  08/734,592

  	
   

  	
  22-Oct-1996

  	
   

  	
  Pending

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002WO1

  	
   

  	
  PCT

  	
   

  	
  GB92/00595

  	
   

  	
  03-Apr-1992

  	
   

  	
  Natl Phase

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002WO5

  	
   

  	
  PCT

  	
   

  	
  US93/06228

  	
   

  	
  29-Jun-1993

  	
   

  	
  Natl Phase

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-002WO6

  	
   

  	
  PCT

  	
   

  	
  US95/06846

  	
   

  	
  25-May-1995

  	
   

  	
  Natl Phase

  	
   

  	
  Andrew D.J.
  Goodearl et al.

  
	
  Title:  GLIAL MITOGENIC FACTORS, THEIR PREPARATION
  AND USE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-028001

  	
   

  	
  United States

  	
   

  	
  08/209,204

  	
   

  	
  08-Mar-1994

  	
   

  	
  Pending

  	
   

  	
  Robert Sklar et
  al.

  
	
  Title:  METHODS FOR TREATING MUSCLE DISEASES AND
  DISORDERS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-028002

  	
   

  	
  United States

  	
   

  	
  08/461,097

  	
   

  	
  05-Jun-1995

  	
   

  	
  Pending

  	
   

  	
  Robert Sklar et
  al.

  
	
  Title:  METHODS FOR TREATING MUSCLE DISEASES AND
  DISORDERS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-028004

  	
   

  	
  United States

  	
   

  	
  08/468,731

  	
   

  	
  06-Jun-1995

  	
   

  	
  Pending

  	
   

  	
  Robert Sklar et
  al.

  
	
  Title:  METHODS FOR TREATING MUSCLE DISEASES AND
  DISORDERS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-030CA1

  	
   

  	
  Canada

  	
   

  	
  2,162,262

  	
   

  	
  06-May-1994

  	
   

  	
  Pending

  	
   

  	
  Robert Sklar et
  al.

  
	
  Title:  METHODS FOR TREATING MUSCLE DISEASES AND
  DISORDERS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-030EP1

  	
   

  	
  Europe

  	
   

  	
  94916690.4

  	
   

  	
  06-May-1994

  	
   

  	
  Pending

  	
   

  	
  Robert Sklar et
  al.

  
	
  Title:  METHODS FOR TREATING MUSCLE DISEASES AND
  DISORDERS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-030JP1

  	
   

  	
  Japan

  	
   

  	
  525593/1994

  	
   

  	
  06-May-1994

  	
   

  	
  Pending

  	
   

  	
  Robert Sklar et
  al.

  
	
  Title:  METHODS FOR TREATING MUSCLE DISEASES AND
  DISORDERS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-030WO1

  	
   

  	
  PCT

  	
   

  	
  US94/05083

  	
   

  	
  06-May-1994

  	
   

  	
  Natl Phase

  	
   

  	
  Robert Sklar et
  al.

  
	
  Title:  METHODS FOR TREATING MUSCLE DISEASES AND
  DISORDERS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-039CA1

  	
   

  	
  Canada

  	
   

  	
  2,215,330

  	
   

  	
  27-Mar-1996

  	
   

  	
  Pending

  	
   

  	
  Thomas A. Reh et
  al.

  
	
  Title:  METHODS OF TREATING DISORDERS OF THE EYE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-039EP1

  	
   

  	
  Europe

  	
   

  	
  96910617.8

  	
   

  	
  27-Mar-1996

  	
   

  	
  Pending

  	
   

  	
  Thomas A. Reh et
  al.

  
	
  Title:  METHODS OF TREATING DISORDERS OF THE EYE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-039JP1

  	
   

  	
  Japan

  	
   

  	
  8-529635

  	
   

  	
  27-Mar-1996

  	
   

  	
  Pending

  	
   

  	
  Thomas A. Reh et
  al.

  
	
  Title:  METHODS OF TREATING DISORDERS OF THE EYE

  

 

4

 

	
  Matter

  Number

  	
   

  	
  Country

  	
   

  	
  Application

  Number

  	
   

  	
  Filing

  Date

  	
   

  	
  Status

  	
   

  	
  Inventors

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-041CA1

  	
   

  	
  Canada

  	
   

  	
  2,204,850

  	
   

  	
  16-Nov-1995

  	
   

  	
  Pending

  	
   

  	
  David I. Gwynne
  et al.

  
	
  Title:  USE OF NEUREGULIN AS MODULATORS OF CELLULAR
  COMMUNICATION

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-041EP1

  	
   

  	
  Europe

  	
   

  	
  95940728.9

  	
   

  	
  16-Nov-1995

  	
   

  	
  Pending

  	
   

  	
  David I. Gwynne
  et al.

  
	
  Title:  USE OF NEUREGULIN AS MODULATORS OF CELLULAR
  COMMUNICATION

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-041JP1

  	
   

  	
  Japan

  	
   

  	
  8-516986

  	
   

  	
  16-Nov-1995

  	
   

  	
  Pending

  	
   

  	
  David I. Gwynne
  et al.

  
	
  Title:  USE OF NEUREGULIN AS MODULATORS OF CELLULAR
  COMMUNICATION

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-041004

  	
   

  	
  United States

  	
   

  	
  09/069,784

  	
   

  	
  20-Mar-2001

  	
   

  	
  Pending

  	
   

  	
  David I. Gwynne
  et al.

  
	
  Title:  USE OF NEUREGULIN AS MODULATORS OF CELLULAR
  COMMUNICATION

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-041005

  	
   

  	
  United States

  	
   

  	
  09/366,886

  	
   

  	
  04-Aug-1999

  	
   

  	
  Pending

  	
   

  	
  David I. Gwynne
  et al.

  
	
  Title:  USE OF NEUREGULIN AS MODULATORS OF CELLULAR
  COMMUNICATION

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-041WO1

  	
   

  	
  PCT

  	
   

  	
  US95/14974

  	
   

  	
  16-Nov-1995

  	
   

  	
  Natl Phase

  	
   

  	
  David I. Gwynne
  et al.

  
	
  Title:  USE OF NEUREGULIN AS MODULATORS OF CELLULAR
  COMMUNICATION

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-043CA2

  	
   

  	
  Canada

  	
   

  	
  2,237,400

  	
   

  	
  12-Nov-1996

  	
   

  	
  Pending

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING DISORDERS OF NON-VISUAL
  SENSORY EPITHELIA

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-043EP2

  	
   

  	
  Europe

  	
   

  	
  96940360.9

  	
   

  	
  12-Nov-1996

  	
   

  	
  Pending

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING DISORDERS OF NON-VISUAL
  SENSORY EPITHELIA

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-043JP2

  	
   

  	
  Japan

  	
   

  	
  518966/97

  	
   

  	
  12-Nov-1996

  	
   

  	
  Pending

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING DISORDERS OF NON-VISUAL
  SENSORY EPITHELIA

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-043WO2

  	
   

  	
  PCT

  	
   

  	
  US96/18031

  	
   

  	
  12-Nov-1996

  	
   

  	
  Natl Phase

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING DISORDERS OF NON-VISUAL
  SENSORY EPITHELIA

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-044AU2

  	
   

  	
  Australia

  	
   

  	
  49744/00

  	
   

  	
  20-Apr-2000

  	
   

  	
  Natl Phase

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING CONGESTIVE HEART
  FAILURE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-044CA2

  	
   

  	
  Canada

  	
   

  	
  2,368,357

  	
   

  	
  20-Apr-2000

  	
   

  	
  Natl Phase

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING CONGESTIVE HEART
  FAILURE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-044EP2

  	
   

  	
  Europe

  	
   

  	
  00931938.5

  	
   

  	
  20-Apr-2000

  	
   

  	
  Natl Phase

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING CONGESTIVE HEART
  FAILURE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-044JP2

  	
   

  	
  Japan

  	
   

  	
  2000-613391

  	
   

  	
  20-Apr-2000

  	
   

  	
  Natl Phase

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING CONGESTIVE HEART
  FAILURE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-044KR2

  	
   

  	
  Korea

  	
   

  	
  2001-7013409

  	
   

  	
  20-Apr-2000

  	
   

  	
  Natl Phase

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING CONGESTIVE HEART
  FAILURE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-044001

  	
   

  	
  United States

  	
   

  	
  09/298,121

  	
   

  	
  23-Apr-2000

  	
   

  	
  Pending

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING CONGESTIVE HEART
  FAILURE

  

 

5

 

	
  Matter

  Number

  	
   

  	
  Country

  	
   

  	
  Application

  Number

  	
   

  	
  Filing

  Date

  	
   

  	
  Status

  	
   

  	
  Inventors

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-044WO2

  	
   

  	
  PCT

  	
   

  	
  US00/10664

  	
   

  	
  20-Apr-2000

  	
   

  	
  Published

  	
   

  	
  Mark Marchionni
  et al..

  
	
  Title:  METHODS OF TREATING CONGESTIVE HEART
  FAILURE

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-048CA2

  	
   

  	
  Canada

  	
   

  	
  2,306,228

  	
   

  	
  08-Oct-1998

  	
   

  	
  Natl Phase

  	
   

  	
  R. McBurney et
  al.

  
	
  Title:  THERAPEUTIC METHODS COMPRISING USE OF
  NEUREGULIN

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-048EP2

  	
   

  	
  Europe

  	
   

  	
  98949803.5

  	
   

  	
  08-Oct-1998

  	
   

  	
  Natl Phase

  	
   

  	
  R. McBurney et
  al.

  
	
  Title:  THERAPEUTIC METHODS COMPRISING USE OF
  NEUREGULIN

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-048JP2

  	
   

  	
  Japan

  	
   

  	
  2000-515608

  	
   

  	
  08-Oct-1998

  	
   

  	
  Natl Phase

  	
   

  	
  R. McBurney et
  al.

  
	
  Title:  THERAPEUTIC METHODS COMPRISING USE OF
  NEUREGULIN

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-048KR2

  	
   

  	
  Korea

  	
   

  	
  2000-7003972

  	
   

  	
  08-Oct-1998

  	
   

  	
  Natl Phase

  	
   

  	
  R. McBurney et
  al.

  
	
  Title:  THERAPEUTIC METHODS COMPRISING USE OF
  NEUREGULIN

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-048002

  	
   

  	
  United States

  	
   

  	
  09/530,884

  	
   

  	
  29-Aug-2000

  	
   

  	
  Natl Phase

  	
   

  	
  R. McBurney et
  al.

  
	
  Title:  THERAPEUTIC METHODS COMPRISING USE OF
  NEUREGULIN

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04585-048WO2

  	
   

  	
  PCT

  	
   

  	
  US98/21349

  	
   

  	
  18-Oct-1998

  	
   

  	
  Pending

  	
   

  	
  R. McBurney et
  al.

  
	
  Title:  THERAPEUTIC METHODS COMPRISING USE OF
  NEUREGULIN

  

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]